



Date accessed 7/8/21

https://www.eloctate.com/index.aspx

period.  
<sup>1</sup>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 013;19:e1-47.  
<sup>2</sup>#1 prescribed based on HTC reported data as of June 2020.

### CONTACT YOUR CoRe

Sanofi Genzyme Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.

ZIP code\*

### GET INFORMED. STAY INFORMED.

Let's stay in touch. We'll occasionally send you important information on Hemophilia A and ELOCTATE. If you're new to ELOCTATE, we'll send you a Bluetooth® speaker so you can listen to patient stories, or if you're already on ELOCTATE, we'll send you this stylish cooler bag.

Email

Bluetooth is a registered trademark of Bluetooth SIG, Inc.

## HOW MUCH DO YOU KNOW?

Whether you're a total newbie or a total pro, there's something to learn about ELOCTATE. Pick your path below, then select the links to get going.

#### IMPORTANT SAFETY INFORMATION AND INDICATION

##### IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and

##### INDICATION

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people



Date accessed 7/8/21

https://www.eoctate.com/resources/microhealth.aspx


ABOUT

PATIENT STORIES

RESOURCES

CONNECT

SEARCH



# HELP TRACK YOUR TREATMENT WITH MICROHEALTH

## STAY ON TOP OF YOUR HEMOPHILIA TREATMENT INFORMATION.

Get text reminders, track infusions and bleeds, access records on the go, scan barcodes to log factor, and more.



### IMPORTANT SAFETY INFORMATION AND INDICATION

#### IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and

#### INDICATION

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people



**Important Safety Information:**

**CONTRAINDICATIONS:** ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

**WARNINGS AND PRECAUTIONS:** Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. [View more](#)

SEARCH

Date accessed 7/6/21

[Request tools to support ELOCTATE in your practice](#)

# ELOCTATE<sup>®</sup> has an established safety profile<sup>1</sup>

ELOCTATE is contraindicated in patients who have had a life-threatening hypersensitivity reaction to ELOCTATE or its excipients. Hypersensitivity reactions, including anaphylaxis, have been reported with ELOCTATE.

## Clinical trial subjects were monitored for neutralizing antibodies to factor VIII

- Zero inhibitors were detected in clinical trials of previously treated patients (PTPs)
- In a clinical trial of previously untreated patients (PUPs), inhibitors were detected in 27% of patients (n=28/103)
  - 14% of patients (n=14/103) developed a high-titer inhibitor
- Formation of neutralizing antibodies (inhibitors) to factor VIII has been reported following administration of ELOCTATE

## Additional warnings and precautions

- Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII
- If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia, and catheter-site thrombosis should be considered



**Important Safety Information:**  
**CONTRAINDICATIONS:** ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.  
**WARNINGS AND PRECAUTIONS:** Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. [View more](#)

SEARCH


Date accessed  
7/8/21

<https://www.eloctatepro.com/the-need>

[Request tools to support ELOCTATE in your practice](#)

# Clinical challenges of hemophilia treatment

**Nearly 80% of bleeds occur in the joints, causing inflammation that can lead to permanent damage, chronic joint pain, and arthropathy<sup>1</sup>**



**>30% of patients with severe hemophilia in their 20s and 30s reported more than**